UBS Boosts Boston Scientific (BSX) Price Target After Strong Q3 Earnings

Boston Scientific Corporation (NYSE:BSX) ranks among the best long-term stocks to buy according to D. E. Shaw. On October 23, UBS maintained its Buy rating on Boston Scientific Corporation (NYSE:BSX) shares, and increased its price target to $140 from $135. The price target raise comes after Boston Scientific’s quarterly results, which showed organic sales and earnings per share growth that surpassed both UBS and consensus expectations, with solid revenue growth of 21.4% year-over-year.

The company generated $5,065 million in net revenue for the third quarter, representing 15.3% year-over-year organic growth. Meanwhile, it produced adjusted earnings per share of $0.75 for the quarter, substantially higher than the $0.71 consensus estimate. Following the results, Boston Scientific Corporation (NYSE:BSX) increased its full-year 2025 outlook, now anticipating roughly 20% growth and adjusted EPS of $3.02-$3.04, up from earlier estimates.

Moreover, the company’s FARAPULSE product line saw roughly 63% organic worldwide expansion, with US growth improving by 40 percentage points on a comp-adjusted basis. The product also experienced faster growth abroad, although at a slower mid-single-digit pace.

According to UBS, Boston Scientific’s WATCHMAN device experienced 35% organic sales growth for the fifth consecutive quarter, as product acceptance continues to climb.

Boston Scientific Corporation (NYSE:BSX) is a global leader in the manufacture of medical devices, including stents, brain stimulation systems, heart monitors, and catheters.

While we acknowledge the potential of BSX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BSX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.